Premium
Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment?
Author(s) -
Fichna J.,
Mokrowiecka A.,
Cygankiewicz A. I.,
Zakrzewski P. K.,
MałeckaPanas E.,
Janecka A.,
Krajewska W. M.,
Storr M. A.
Publication year - 2012
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/j.1365-2982.2012.01999.x
Subject(s) - transient receptor potential channel , trpv4 , colitis , inflammation , blockade , medicine , inflammatory bowel disease , gastrointestinal tract , inflammatory bowel diseases , trpv1 , receptor , ulcerative colitis , pharmacology , immunology , disease
Recent reports suggested that the activation of Transient Receptor Potential Vanilloid 4 (TRPV4) receptors in the gastrointestinal tract has pro‐inflammatory effects. In this study, we demonstrated for the first time that TRPV4 mRNA expression is up‐regulated in patients with inflammatory bowel diseases (IBD). Furthermore, selective blockade of TRPV4 in the 2,4,6‐trinitrobenzenesulfonic acid animal model alleviates colitis and pain associated with the intestinal inflammation. Our study indicates that TRPV4 may play a role in mechanisms of defense in intestinal inflammation and that TRPV4 may be an attractive target for future systemic or topic anti‐inflammatory treatment in patients with IBD.